Investigating a key pathway involved in diabetes complications
Official title: Probing an Unexplored Intracellular Pathway in Diabetes Pathogenesis
Funded at Lankenau Institute for Medical Research · NIH-10766705 · Data updated 2026-11-12
This study is looking at how a substance called 3-deoxyglucosone (3DG) affects people with diabetes, especially in causing kidney problems, and it's using mice to find out more about it so that new treatments can be developed to help manage diabetes better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lankenau Institute for Medical Research NIH-funded |
| Lab location | 1 site (Wynnewood, United States) |
| Project start | February 1, 2022 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $515,870 |
| NIH project number | 5R01DK131173-03 |
| Project ID | NIH-10766705 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with type-2 diabetes, particularly those experiencing complications such as diabetic nephropathy.
✕Less likely to help
Patients without diabetes or those with type-1 diabetes may not benefit from this research.
What this research studies
This research focuses on understanding how a specific compound, 3-deoxyglucosone (3DG), contributes to diabetes complications by damaging cells and inflaming blood vessels. The study aims to measure the levels of 3DG in tissues and explore its relationship with diabetic nephropathy using a mouse model of type-2 diabetes. Researchers are also developing new methods to study an enzyme that may help repair damaged proteins but also produces 3DG. By uncovering these mechanisms, the research seeks to identify potential therapeutic targets for improving diabetes management.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments that reduce complications associated with diabetes.
How similar studies have gone: Previous research has shown promising results in understanding the role of advanced glycation end products in diabetes, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Lankenau Institute for Medical Research
Wynnewood, United States Active
Researchers
- Principal investigator: Prendergast, George C — Lankenau Institute for Medical Research
- Study coordinator: Prendergast, George C
Related research
Other NIH-funded projects on the same topics.
-
HEARTS hypertension and diabetes care in Guatemala
This grant tests how well the HEARTS primary care model works in Guatemala to improve blood pressure and blood sugar control for patients.
-
Retinal signals in early diabetes and how they affect vision
This grant looks at how diabetes changes the signals in the retina that control vision, with a focus on inner retinal cells and how these changes may lead to vision problems.
-
Integrated Heart Health: A HEARTS-based approach to hypertension and diabetes in Guatemala
A study tests a team-based, stepwise care model to improve blood pressure and blood sugar control for people with both hypertension and diabetes in Guatemala.
-
Bringing WHO HEARTS-D diabetes care into Bangladesh cities
A program to help urban clinics in Bangladesh adopt WHO HEARTS-D guidelines to improve detection, treatment, and control of type 2 diabetes.
-
AI-powered fundus imaging to screen for type 2 diabetes
A mobile AI tool uses eye images to help screen adults for type 2 diabetes in clinics or communities.
-
AI-powered eye imaging to screen for type 2 diabetes with a mobile phone
A plan to use AI on smartphone retinal images to help spot type 2 diabetes early, especially in people who may not have easy access to care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.